The obesity of bone

Therapeutic Advances in Endocrinology and Metabolism

Volumn 6, Issue 6, 2015, Pages 273-286

  Greco, Emanuela A ^a   Lenzi, Andrea ^a   Migliaccio, Silvia ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

adipocyte; adipokines; bone derived factors; fat bone marrow; mesenchymal stem cell; obesity; osteoblast; osteoporosis

Indexed keywords

ADIPONECTIN; GHRELIN; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

BODY FAT; BODY WEIGHT; BONE DENSITY; BONE MARROW; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE METABOLISM; CALORIC INTAKE; CELL TRANSDIFFERENTIATION; ENERGY BALANCE; FRAGILITY FRACTURE; HUMAN; OBESITY; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 84947423623     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018815611004     Document Type: Review

References (113)

1. Abdallah B. Ditzel N. Mahmood A. Isa A. Traustadottir G. Schilling A. et al. (2011) DLK 1 is a novel regulator of bone mass that mediates estrogen deficiency induced bone loss in mice. J Bone Miner Res 26: 1457–1471.
2. Abdallah B. Jensen C. Gutierrez G. Leslie R. Jensen T. Kassem M. (2004) Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J Bone Miner Res 19: 841–852.
3. Ahmad R. Al-Mass A. Al-Ghawas D. Shareif N. Zghoul N. Melhem M. et al. (2013) Interaction of osteopontin with il-18 in obese individuals: implications for insulin resistance. PloS ONE 8: 639–644.
4. Akune T. Ohba S. Kamekura S. Yamaguchi M. Chung U. Kubota N. et al. (2004) PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113: 846–855.
5. Albala C. Yanez M. Devoto E. Sostin C. Zeballos L. Santos J. (1996) Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord 20: 1027–1032.
6. Anderson D. Maraskovsky E. Billingsley W. Dougall W. Tometsko M. Roux E. et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (6656): 175–179.
7. Aubin J. (1998) Bone stem cells. J Cell Biochem 30–31(Suppl.): 73–82.
8. Baldock P. Sainsbury A. Couzens M. Enriquez R. Thomas G. Gardiner E. et al. (2002). Hypothalamic Y 2 receptors regulate bone formation. J Clin Invest 109: 915–921.
9. Bredella M. Torriani M. Ghomi R. Thomas B. Brick D. Gerweck A. et al. (2011) Determinants of bone mineral density in obese premenopausal women. Bone 48: 748–754.
10. Burke Z. Tosh D. (2005) Therapeutic potential of transdifferentiated cells. Clin Sci (Lond) 108: 309–321.
11. Cao J. (2011) Effects of obesity on bone metabolism. J Orthop Surg Res 6: 30.
12. Cenci S. Weitzmann M. Roggia C. Namba N. Novack D. Woodring J. et al. (2000) Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J Clin Invest 106: 1229–1237.
13. Cohen A. Dempster D. Recker R. Lappe J. Zhou H. Zwahlen A. et al (2013) Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab 98 (6): 2562–72.
14. Colaianni G. Brunetti G. Faienza M. Colucci S. Grano M. (2014) Osteoporosis and obesity: role of Wnt pathway in human and murine models. World J Orthop 5: 242–246.
15. Compston J. Flahive J. Hosmer D. Watts N. Siris E. Silverman S. et al. (2014) Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res 29: 487–493.
16. Considine R. Sinha M. Heiman M. Kriauciunas A. Stephens T. Nyce M. et al. (1996) Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 34: 292–295.
17. Copês R. Comim F. Langer F. Codevilla A. Sartori G. et al. (2015) Obesity and Fractures in Postmenopausal Women: A Primary-care Cross-Sectional Study at Santa Maria, Brazil. J Clin Densitom 18: 165–171.
18. Covey S. Wideman R. McDonald C. Unniappan S. Huynh F. Asadi A. et al. (2006) The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab 4: 291–302.
19. Dodds A. Merry K. Littlewood A. Gowen M. (1994) Expression of mRNA for IL 1 beta, IL 6 and TGF beta 1 in developing human bone and cartilage. J Histochem Cytochem 42: 733–744.
20. Ducy P. Amling M. Takeda S. Priemel M. Schilling A. Beil F. et al. (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197–207.
21. Duque G. Macoritto M. Dion N. Ste-Marie L. Kremer R. (2005) 1,25(OH)2D3 acts as a bone-forming agent in the hormone independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab 288: E723–E730.
22. Duque G. Macoritto M. Kremer R. (2004) Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Biogerontology 5: 421–429.
23. Eriksen E. Colvard D. Berg N. Graham M. Mann K. Spelsberg T. et al. (1988) Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241: 84–86.
24. Fasshauer M. Klein J. Krahlisch S. Lossner U. Klier M. Bluher M. et al. (2003) GH is a positive regulator of tumor necrosis factor-alpha-induced adipose related protein in 3T3-L1 adipocytes. J Endocrinol 178: 523–531.
25. Fasshauer M. Klein J. Neumann S. Eszlinger M. Paschke R. (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290: 1084–1089.
26. Ferron M. Hinoi E. Karsenty G. Ducy P. (2008) Osteocalcin differentially regulates beta cell and dipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 105: 5266–5270.
27. Festa A. D'Agostino R. Jr Tracy R. Haffner S. (2002) Insulin resistance atherosclerosis study. Elevated levels of acute-phase proteins and plasminogen activator inhibior-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51: 1131–1137.
28. Fukumoto S. Martin T. (2009) Bone as an endocrine organ. Trends Endocrinol Metab 20: 230–236.
29. Gambacciani M. Ciaponi M. Cappagli B. Piaggesi L. de Simone L. Orlandi R. et al. (1997) Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 82: 414–417.
30. Gao B. Huang Q. Lin Y. Wei B. Guo Y. Sun Z. et al. (2014) Dose-dependent effect of estrogen suppresses the osteo-adipogenic transdifferentiation of osteoblasts via canonical Wnt signaling pathway. PLOSE ONE 9: e-99137.
31. Gimble J. Robinson C. Wu X. et al. (1996) Peroxisome proliferator activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50: 1087–1094.
32. Gimble J. Zvonic S. Floyd Z. Kassem M. Nuttall M. (2006) Playing with bone and fat. J Cell Biochem 98: 251–266.
33. Gomez-Ambrosi J. Rodrıguez A. Catalan V. Fruhbeck G. (2008) The bone-adipose axis in obesity and weight loss. Obes Surg 18: 1134–1143.
34. Goulding A. Taylor R. (1998) Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 63: 456–458.
35. Grant S. Thorleifsson G. Reynisdottir I. Benediktsson R. Manolescu A. Sainz J. et al. (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38: 320–323.
36. Greco E. Fornari R. Rossi F. Santiemma V. Prossomariti G. Annoscia C. et al. (2010) Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index. Int J Clin Pract 64: 817–820.
37. Greco E. Francomano D. Fornari R. Marocco C. Lubrano C. Papa V. et al. (2013) Negative association between trunk fat, insulin resistance and skeleton in obese women. World J Diabetes 4: 31–39.
38. Guo Y. Xiong D. Shen H. Zhao L. Xiao P. Guo Y. et al. (2006) Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. J Med Genet 43: 798–803.
39. Hinoi E. Gao N. Jung D. Yadav V. Yoshizawa T. Myers M. Jr et al. (2008) The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 183: 1235–1242.
40. Holecki M. Chudek J. Titz-Bober M. Więcek A. Zahorska-Markiewicz B. Duława J. (2012) Changes of bone mineral density in obese perimenopausal women during 5-year follow-up. Pol Arch Med Wewn 122: 139–147.
41. Ho-Pham L. Nguyen U. Nguyen T. (2014) Association between lean mass, fat mass, and bone mineral density: a meta-analysis. J Clin Endocrinol Metab 99: 30–38.
42. Hotamisligil G. Arner P. Caro J. Atkinson R. Spiegelman B. (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409–2415.
43. Hu F. (2003) Overweight and obesity in women: health risks and consequences. J Women Health (Larchmt) 12: 163–172.
44. Jurimae J. Rembel K. Jurimae T. Rehand M. (2005) Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 37: 297–302.
45. Justesen J. Stenderup K. Ebbesen E. Mosekilde L. Steiniche T. Kassem M. (2001) Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2: 165–171.
46. Kado D. Huang M. Karlamangla A. Barrett-Connor E. Greendale G. (2004) Hyperkyphotic posture predicts mortality in older community-dwelling men and women: a prospective study. J Am Geriatr Soc 52: 1662–1667.
47. Kadowaki T. Yamauchi T. (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439–451.
48. Kajkenova O. Lecka-Czernik B. Gubrij I. Hauser S. Takahashi K. Parfitt A. et al. (1997) Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6: a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res 12: 1772–1779.
49. Kamiya Y. Chen J. Xu M. Utreja A. Choi T. Drissi H. et al. (2013) Increased mandibular condylar growth in mice with estrogen receptor beta deficiency. J Bone Miner Res 28: 1127–1134.
50. Kiefer F. Zeyda M. Todoric J. Huber J. Geyeregger R. Weichhart T. et al. (2008) Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 149: 1350e1357.
51. Kim H. (2010) New understanding of glucocorticoid action in bone cells. BMB Rep 43: 524–529.
52. Kim K. Shin D. Lee S. Im J. Lee D. (2010) Relation between obesity and bone mineral density and vertebral fractures in korean postmenopausal women. Yonsei Med J 51: 857–863.
53. Komm B. Terpening C. Benz D. Graeme K. Gallegos A. Korc M. et al. (1988) Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241: 81–84.
54. Kontogianni M. Dafni U. Routsias J. Skopouli F. (2004) Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 19: 546–555.
55. Krishnan V. Bryant H. Macdougald O. (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202–1209.
56. Lecka-Czernik B. Moerman E. Grant D. Lehmann J. Manolagas S. Jilka R. (2002) Divergent effects of selective peroxisome proliferator activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143: 2376–2384.
57. Lee N. Sowa H. Hinoi E. Ferron M. Ahn J. Confavreux C. et al. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130: 456–469.
58. Magni P. Dozio E. Galliera E. Ruscica M. Corsi M. (2010) Molecular aspects of adipokine–bone interactions. Curr Mol Med 10: 522–532.
59. Mani A. Radhakrishnan J. Wang H. Mani A. Mani M. Nelson-Williams C. et al. (2007) LRP 6 mutation in a family with early coronary disease and metabolic risk factors. Science 315: 1278–1282.
60. Mao L. Kawao N. Tamuea Y. Okumoto K. Okada K. Yano M. et al. (2014) Plasminogen activator inhibitor-1 is involved in impaired bone repair associated with diabetes in female mice. PloS ONE 9: e92686.
61. Martin R. Zissimos S. (1991) Relationships between marrow fat and bone turnover in ovariectomized and intact rats. Bone 12: 123–131.
62. Martin S. Qasim A. Reilly M. (2008) Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 52: 1201–1210.
63. Menagh P. Turner R. Jump D. Wong C. Lowry M. Yakar S. et al. (2010) Growth hormone regulates the balance between bone formation and bone marrow adiposity. J Bone Miner Res 25: 757–768.
64. Migliaccio S. Davis V. Gibson M. Gray T. Korach K. (1992) Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor. Endocrinology 130: 2617–2624.
65. Migliaccio S. Francomano D. Bruzziches R. Greco E. Fornari R. et al. (2013) Trunk fat negatively influences skeletal and testicular functions in obese men: clinical implications for the aging male. Int J Endocrinol 2013: 182753.
66. Moerman E. Teng K. Lipschitz D. Lecka-Czernik B. (2004) Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 3: 379–389.
67. NIH (2001) Consensus Development Panel on Osteoporosis. JAMA 285: 785–795.
68. Pacifici R. Brown C. Puscheck E. Friedrich E. Slatopolsky E. Maggio D. et al. (1991) Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A 88: 5134–5138.
69. Pajvani U. Du X. Combs T. Berg A. Rajala M. Schulthess T. et al. (2003) Structure-function studies of the adipocytes-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278: 9073–9085.
70. Pierroz D. Rufo A. Bianchi E. Glatt V. Capulli M. Rucci N. et al. (2009) β-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res 24: 775–784.
71. Premaor M. Compston J. Fina Avilés F. Pagès-Castellà A. et al (2013) The association between fracture site and obesity in men: a population-based cohort study. J Bone Miner Res 28: 1771–1777.
72. Qiu W. Chen L. Kassem M. (2011) Activation of non-canonical Wnt/JNK pathway by Wnt3a is associated with differentiation fate determination of human bone marrow stromal (mesenchymal) stem cells. Biochem Biophys Res Commun 413: 98–104.
73. Reid I. (2002) Relationships among body mass, its components, and bone. Bone 31: 547–555.
74. Reid I. Ames R. Evans M. Sharpe S. Gamble G. France J. et al. (1992 a) Determinants of total body and regional bone mineral density in normal postmenopausal women – a key role for fat mass. J Clin Endocrinol Metab 75: 45–51.
75. Reid I. Legge M. Stapleton J. Evans M. Grey A. (1995) Regular exercise dissociates fat mass and bone density in premenopausal women. J Clin Endocrinol Metab 80: 1764–1768.
76. Reid I. Plank L. Evans M. (1992 b) Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab 75: 779–782.
77. Ribot C. Tremollieres F. Pouilles J. Bonneu M. Germain F. Louvet J. (1987) Obesity and postmenopausal bone loss: the influence of obesity on vertebral density and bone turnover in postmenopausal women. Bone 8: 327–331.
78. Rodriguez J. Montecinos L. Rios S. Reyes P. Martinez J. (2000) Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J Cell Biochem 79: 557–565.
79. Rosen C. Bouxein M. (2006) Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2: 35–43.
80. Rossner S. (2002) Obesity: the disease of the twenty-first century. Int J Obes Relat Metab Disord 26(Suppl. 4): S2–S4.
81. Rundle C. Wang X. Werdegal J. Mohan S. Lau K. (2008) Fracture healing in mice deficient in plasminogen activator inhibitor-1. Calcif Tissue Int 83: 276–284.
82. Sainsbury A. Schwarzer C. Couzens M. Fetissov S. Furtinger S. Jenkins A. et al. (2002) Important role of hypothalamic Y 2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci U S A 99: 8938–8943.
83. Sarac F. Basoglu O. Gunduz C. Bayrak H. Biray-Avci C. Akcicek F. (2011) Association of osteopontin and tumor necrosis factor-alpha levels with insulin resistance in obese patients with obstructive sleep apnea syndrome. J Endocrinol Invest 34: 528–533.
84. Scatena M. Liaw L. Giachelli C. (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27: 2302e2309.
85. Schilling T. Kuffner R. Klein-Hitpass L. Zimmer R. Jakob F. Schutze N. (2008) Microarray analyses of transdifferentiated mesenchymal stem cells. J Cell Biochem 103: 413–433.
86. Sekiya I. Larson B. Vuoristo J. Cui J. Prockop D. (2004) Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J Bone Miner Res 19: 256–264.
87. Simonet W. Lacey D. Dunstan C. Kelley M. Chang M. Luthy R. et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone Density. Cell 89: 309–319.
88. Sims N. Jenkins B. Quinn J. Nakamura A. Glatt M. Gillespie M. et al. (2004) Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 113: 379–389.
89. Soeki T. Kishimoto I. Schwenke D. Tokudome T. Horio T. Yoshida M. et al. (2007) Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 294: H426–H432.
90. Sogaard A. Holvik K. Omsland T. Tell G. Dahl C. Schei B. et al. (2015) Abdominal obesity increases the risk of hip fracture. A population-based study of 43,000 women and men aged 60–79 years followed for 8 years. Cohort of Norway. J Intern Med 277: 306–317.
91. Song L. Tuan R. (2004) Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. FASEB J 18: 980–982.
92. Song L. Zhao J. Zhang X. Li H. Zhou Y. (2013) Icariin induces osteoblast proliferation, differentiation and mineralization through estrogen receptor mediated ERK and JNK signal activation. Eur J Pharmacol 714: 15–22.
93. Steppan C. Crawford D. Chidsey-Frink K. Ke H. Swick A. (2000) Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 92: 73–78.
94. Taguchi Y. Yamamoto M. Yamate T. Lin S. Mocharla H. de Togni P. et al. (1998) Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 110: 559–574.
95. Takeda S. (2008) Effect of obesity on bone metabolism. Clin Calcium 18: 632–637.
96. Thomas T. (2004) The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 4: 295–300.
97. Thomas T. Gori F. Khosla S. Jensen M. Burguera B. Riggs B. (1999) Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140: 1630–1638.
98. Thommesen L. Stunes A. Monjo M. Grosvik K. Tamburstuen M. Kjobli E. et al. (2006) Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 99: 824–834.
99. Tilg H. Moschen A. (2008) Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14: 222–231.
100. Ukkola O. (2002) Resistin – a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 147: 571–574.
101. van der Lely A. Tschop M. Heiman M. Ghigo E. (2013) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25: 426–457.
102. van der Velde M. van der Eerden B. Sun Y. Almring J. van der Ley A. Delhhanty P. et al. (2013) An age-dependent interaction with leptin unmasks ghrelin's bone protective effects. Endocrinology 154: 3951.
103. Vendrell J. Broch M. Vilarrasa N. Molina A. Gomez J. Gutierrez C. et al. (2004) Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obes Res 12: 962–971.
104. Vozarova B. Weyer C. Hanson K. Tataranni P. Bogardus C. Pratley R. (2001) Circulating IL-6 in relation to adiposity, insulin action and insulin secretion. Obes Res 9: 414–417.
105. Wannenes F. Papa V. Greco E. Fornari R. Marocco C. Baldari C. et al (2014) Abdominal Fat and Sarcopenia in Women Significantly Alter Osteoblasts Homeostasis In Vitro by a WNT/ β -Catenin Dependent Mechanism. Int J Endocrinol 2014: 278316.
106. Watts N. (2014) GLOW investigators. Insights from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Nat Rev Endocrinol 10: 412–422.
107. Wei S. Kitaura H. Zhou P. Ross P. Teitelbaum S. (2005) IL-1 mediates TNF-induCEOsteoclastogenesis. J Clin Invest 115: 282–290.
108. WHO (2000) Obesity: Preventing and Managing the Global Epidemic. Report of a WHO consultation. WHO Technical Report Series 894. Geneva: World Health Organization.
109. Yamauchi T. Kamon J. Waki H. Terauchi Y. Kubota N. Hara K. et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with body lipoatrophy and obesity. Nat Med 7: 941–946.
110. Yang S. Nguyen N. Center J. Eisman J. Nguyen T. (2013) Association between abdominal obesity and fracture risk: a prospective study. J Clin Endocrinol Metab 98: 2478–2483.
111. Yang S. Shen X. (2015) Association and relative importance of multiple obesity measures with bone mineral density: the National Health and Nutrition Examination Survey 2005–2006. Arch Osteoporos 10: 14.
112. You J. Ji H. Chang K. Yoo M. Yang H. Jeong I. et al. (2013) Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans. Mol Med Rep 8: 579–584.
113. Zeyda M. Gollinger K. Todoric J. Kiefer F. Keck M. Aszmann O. et al. (2011) Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology 152: 2219–2227.